What sermorelin and ipamorelin are, who promotes the pairing, the zero trials of the combination, each component's reported doses, and the units per draw.
This page reports the pairing of sermorelin with ipamorelin: what each is, who promotes the combination and what they claim for it, what the human evidence holds when it is counted, the doses reported for each with their sources, and how the two vials are reconstituted and drawn. It presents no protocol and ranks nothing. Every figure carries its source and the date it was read.
Sermorelin is GHRH(1-29), the first 29 amino acids of growth-hormone-releasing hormone and the shortest fragment with the hormone's full activity; it acts on the pituitary's GHRH receptor and once held an FDA label. Ipamorelin is a synthetic five-amino-acid peptide (C38H49N9O5, molecular weight 711.9, PubChem CID 9831659, read 2026-09-18) that acts on the ghrelin receptor, a second route to growth-hormone release; it has never held a label. The pairing is sold on the idea that the two routes add up. Medibact's sermorelin guide and ipamorelin guide cover each compound's mechanism and evidence in full.
The first page of results for "sermorelin and ipamorelin" is protocol sites, compounding-pharmacy blogs and telehealth clinic pages (read 2026-09-18). Their claims, in their own terms: the pair "targets both the GHRH receptor and the ghrelin receptor", "enhances growth hormone pulse amplitude and duration", and suits people who want "a gentler" alternative to CJC-1295. The figures they give for the pair disagree with one another, which is reported below. None cites a study of the two together, because there is none.
What the human evidence holds, counted
|
Sermorelin |
Ipamorelin |
The pair |
| Approved label |
GEREF, withdrawn June 2009; not for safety or effectiveness (Federal Register, 2013-03-04) |
none; DailyMed zero records (2026-09-18) |
none |
|---|
| ClinicalTrials.gov registrations (2026-09-18) |
27 |
3 |
0 |
|---|
| PubMed papers under the trial filter |
0 under a title-and-abstract filter; 17 human-tagged records |
2 (1999 pharmacokinetics; 2014 postoperative ileus) |
0; 5 reviews mention both |
|---|
| Populations studied |
children with growth hormone deficiency; adults in diagnostic tests; HIV lipodystrophy; a terminated study in older adults (NCT01410799) |
healthy men (intravenous); bowel-resection patients (intravenous) |
nobody |
|---|
Sermorelin's record is the larger and the older. Prakash and Goa's 1999 review (PMID 18031173) states that once-daily subcutaneous sermorelin at 30 mcg/kg at bedtime was effective in some prepubertal children with idiopathic growth hormone deficiency, with height velocity gains sustained over 12 months, that the same total dose given by continuous infusion or in three divided doses produced smaller gains than once-daily somatropin, and that 1 mcg/kg intravenously is a diagnostic test. The 27 registrations on ClinicalTrials.gov are growth-hormone-deficiency, HIV-lipodystrophy, abdominal-obesity, acromegaly, subfertility and diagnostic-test studies; several use the compound only as a stimulation test. None has a muscle or body-composition endpoint in trained healthy adults, and a three-month trial in older adults was terminated.
Ipamorelin's record is two intravenous trials. Gobburu et al. (Pharmaceutical Research 1999, PMID 10496658) infused five rates from 4.21 to 140.45 nmol/kg over 15 minutes into healthy men, eight per dose, and found a terminal half-life of about 2 hours and a single episode of growth-hormone release peaking at 0.67 hours. Beck et al. (International Journal of Colorectal Disease 2014, PMID 25331030; NCT00672074) infused 0.03 mg/kg twice daily for up to 7 days in 114 bowel-resection patients: the median time to a tolerated solid meal was 25.3 hours against 32.6 on placebo, p = 0.15, with no significant difference on any efficacy analysis. The second Helsinn trial, NCT01280344, tested 0.03 and 0.06 mg/kg two or three times daily in 320 patients and posted no results. That is the whole human record.
Reported doses, with sources
| Component |
Kind of source |
Figure |
Date |
| Sermorelin |
former label (paediatric) |
30 mcg/kg once daily at bedtime; 1 mcg/kg intravenously as a test |
Prakash and Goa 1999; Federal Register 2013 |
| Sermorelin |
arithmetic on that label |
30 mcg/kg is 1.8 mg at 60 kg, 2.1 mg at 70 kg, 2.7 mg at 90 kg |
this page |
| Sermorelin |
compounding and clinic pages |
200 to 300 mcg at night; some pages 100 mcg rising to 400 or 500 mcg |
read 2026-09-18 |
| Ipamorelin |
trial protocol |
3 to 100 mcg/kg intravenously over 15 minutes |
Gobburu 1999 |
| Ipamorelin |
trial protocol |
0.03 to 0.06 mg/kg intravenously two or three times daily, up to 7 days |
Beck 2014; NCT01280344 |
| Ipamorelin |
clinic and protocol pages |
100 to 300 mcg under the skin, one to three times a day |
read 2026-09-18 |
| The pair |
clinic and protocol pages |
250 mcg of each once daily; 100 to 200 mcg sermorelin with 50 to 100 mcg ipamorelin twice daily; 300 mcg of each five days a week |
read 2026-09-18 |
The arithmetic row is there because the gap it shows is the page's most useful fact: the one labelled sermorelin dose, scaled to an adult's weight, is about ten times the figures circulating for adults, and it was a paediatric dose measured on height. Neither figure is a recommendation.
Reconstitution and the units per draw
Concentration is the milligrams in the vial divided by the millilitres of water; the draw on a U-100 syringe is the quantity in mg divided by that concentration, times 100. Both compounds are sold in 5 mg and 10 mg vials, the sizes the site's calculators carry.
| Vial |
Water |
Concentration |
Quantity |
Units (U-100) |
| Sermorelin 5 mg |
2 mL |
2.5 mg/mL |
200 mcg |
8 units |
| Sermorelin 5 mg |
2 mL |
2.5 mg/mL |
300 mcg |
12 units |
| Sermorelin 10 mg |
2 mL |
5 mg/mL |
300 mcg |
6 units |
| Sermorelin 5 mg |
3 mL |
1.67 mg/mL |
500 mcg |
30 units |
| Ipamorelin 5 mg |
2 mL |
2.5 mg/mL |
100 mcg |
4 units |
| Ipamorelin 5 mg |
2 mL |
2.5 mg/mL |
250 mcg |
10 units |
| Ipamorelin 10 mg |
2 mL |
5 mg/mL |
300 mcg |
6 units |
| Ipamorelin 5 mg |
3 mL |
1.67 mg/mL |
100 mcg |
6 units |
Two vials mean two draws and two calculations, and the two peptides can be drawn in any proportion. A pre-mixed vial fixes the proportion at fill time, so a single draw delivers both in whatever ratio the vial holds. The blend calculator does the per-component arithmetic for either case; the sermorelin calculator and ipamorelin calculator cover each vial at any water volume, and the insulin syringe units page covers the scale and the barrels.
Every human figure above omits the stack, and most omit the route. Sermorelin's label dose was subcutaneous, nightly and paediatric; ipamorelin's trial doses were intravenous infusions in surgical patients and healthy volunteers. No human study has given ipamorelin under the skin, no study has given the two together, and none has measured muscle, fat or performance in a healthy adult. Frequency, duration and population are therefore known only for other purposes, and the circulating figures for the pair omit any origin at all.
Status
Ipamorelin acetate was placed in Category 2 of FDA's interim 503A bulks list in September 2023, the category for substances FDA identified as presenting significant safety risks (Alliance for Pharmacy Compounding update, 2023-09-29); an FDA Law Blog post of 2026-04-21 reports FDA moving peptides scheduled for advisory review out of Category 2 in 2026. Sermorelin is not on that list; with its approvals withdrawn and FDA's 2013 finding that the withdrawal was not for safety or effectiveness, it is prepared by compounding pharmacies and has no marketed label. FDA's own list pages refused this site's requests on 2026-09-18, so their current text is not quoted.
Related pages
The muscle-growth stack page counts the other growth-hormone-axis pairings; the site's CJC-1295 with ipamorelin article and tesamorelin with ipamorelin article cover the two combinations most often compared with this one; the stacks hub indexes every combination page; the sermorelin dosage page and ipamorelin dosage page hold each compound's reported range with its source, indexed on the dosage hub.
This page does not recommend the pairing, a dose, a schedule or a vendor. It reports what one withdrawn label, two registries, two trials and the promoting pages state, each with its date, and it does the arithmetic on the vials.
Sources and dates
Opened 2026-09-18: the ClinicalTrials.gov v2 API for sermorelin (27), ipamorelin (3) and the pair (0), with the records NCT00672074, NCT01280344 and NCT01410799; the DailyMed SPL search API for sermorelin, GEREF and ipamorelin (zero records each); the Federal Register notice of 2013-03-04 on GEREF (via GovInfo); PubMed through the NCBI E-utilities for sermorelin and ipamorelin with the trial-type filter and for papers mentioning both (5), with the abstracts of PMID 18031173, 10496658 and 25331030; PubChem CID 9831659 for ipamorelin's formula and molecular weight; the Alliance for Pharmacy Compounding's 503A categories update of 2023-09-29 and the FDA Law Blog post of 2026-04-21; protocol, compounding-pharmacy and clinic pages carrying the circulating figures, read the same day. Corrections go to the contact page.
